Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus by Draenert, Rika et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $8.00
Vol. 203, No. 3,  March 20, 2006  529–539  www.jem.org/cgi/doi/10.1084/jem.20052116
529
Understanding HIV evolution, adaptive immu-
nity, and disease pathogenesis is complicated by 
genetic diversity among infecting viruses. HIV 
is defi  ned by diff  erent clades, which vary from 
one another in some regions by 30% or more; 
even within a single clade, the overall amino 
acid variability may be 20% in their envelope 
proteins (1). Given the high replication rate of 
this retrovirus, and the inherent errors in re-
verse transcription, it is estimated that a muta-
tion arises within every amino acid position of 
each HIV-1 protein every day, although struc-
tural and functional constraints likely limit the 
outgrowth of many variants (2–6). The poten-
tial impact of viral variability on disease patho-
genesis is suggested by studies of viral infections 
in genetically identical mice, where it has been 
shown that as few as two amino acid changes in 
the entire viral genome can result in the diff  er-
ence between an infection that is successfully 
contained by the immune system versus one 
that leads to chronic viremia and death (7).
Although the macaque model of AIDS vi-
rus infection has been able to control for the 
infecting virus, no studies have been able to 
address HIV evolution after acute infection in 
the identical host genetic context. In humans, 
examination of immune responses in geneti-
cally related individuals presumably infected 
with the same virus has shown discordance in 
targeted epitopes and viral variants that evolve 
(8), but no studies have examined these issues 
early after infection in monozygotic twins. In 
mouse models of chronic viral infection, such 
as lymphocytic choriomeningitis virus, the 
dominant and subdominant T cell responses 
are highly predictable (9), but such studies have 
not been possible in rapidly evolving human 
virus infections.
Here, we evaluate the unique situation of 
monozygotic twins that were simultaneously 
infected with the same HIV-1 strain at the age 
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of 21 yr. Over a period of 30 mo of follow up, the develop-
ment of cellular and humoral immune responses and viral 
evolution were studied in this setting that controls for initial 
host and viral diversity. The results, compared with a third 
brother who was infected with the twins’ virus  13 mo later, 
indicate a striking degree of concordance in immune selection 
pressure and viral evolution in HIV infection, suggesting that 
HIV is constrained by restricted pathways to immune eva-
sion, which has important implications for vaccine design.
RESULTS
HIV-1 disease course in monozygotic adult twins infected 
with the same virus
TW1 and TW2 are monozygotic twins diagnosed with pri-
mary HIV infection at age 21, based on routine serologic 
screening done as a result of the risk factor of injection drug 
use. A brother (BR3) who also used injection drugs serocon-
verted 13 mo later. Because the twins reported only a single 
episode of needle sharing with others, and they also shared 
needles with their brother, pol and env genes from all three 
brothers were sequenced to determine if they might be in-
fected with the same virus.
When compared with other viral isolates, all the se-
quences from viruses infecting TW1, TW2, and BR3 clus-
tered together with a mean genetic diversity of the pol gene 
of 0.3 ± 0.1% and a maximum distance of 1% (Fig. 1 A). [ID]FIG1[/ID] In 
contrast, the mean genetic diversity among randomly selected 
sequences from local epidemiologically unrelated HIV-
  infected individuals included in the analysis was 4.4 ± 0.3%. 
Similar phylogenetic analysis on the env gene estimated 
a mean genetic diversity of 3.2 ± 0.2% among the siblings’ 
viruses over the course of infection. The high degree of 
genetic similarity among viral isolates obtained from all three 
siblings indicates that they were infected by the same viral 
strain during needle sharing.
Longitudinal analysis of plasma RNA and CD4 cell counts 
revealed similar trajectories in both twins during the fi  rst 3 yr 
of infection, at which point TW1 died from an injection 
drug overdose (Fig. 1 B). Similar analyses in BR3, who shared 
a single class I A, B, and C haplotype with the twins, likewise 
revealed a very similar viral load, but a more rapid decline in 
CD4 count after infection. These data show similarity in dis-
ease course as defi  ned by viral load and CD4 cell count in 
persons of identical genetic background infected with the 
same strain of virus.
Evolution of virus-specifi  c T cell responses
The only studies evaluating HIV-specifi  c CD8 T cell re-
sponses in persons with the same HLA class I alleles revealed 
diff  erences in these responses years after infection (8, 10), but 
no studies have examined these events in the critical initial 
period of acute infection. We screened both HIV-infected 
twins independently in an IFN-γ Elispot assay for detection 
of antigen-specifi  c T cell responses using a set of overlapping 
15–19 amino acid peptides spanning all expressed HIV pro-
teins (11, 12). At the fi  rst time point available (6 mo after in-
fection), 16 responses directed at fi  ve viral proteins (Gag, Pol, 
Vpr, Env, and Nef) were detectable in each of the twins, 15 
of which were identical (Fig. 2 and Fig. 3 A). [ID]FIG2[/ID][ID]FIG3[/ID] Moreover, the 
two strongest responses targeted in the early phase of infec-
tion were the same, both of which were determined to be 
B*4001-restricted CD8 T cell responses: IL9 in Pol (RT) 
and KL9 in Nef.
Conversely, each of the twins had a single subdominant 
response that could not be detected in the other at the earliest 
time point, TW1 in Nef and TW2 in Env (Fig. 2 and Fig. 3 B); 
both remained minor responses or disappeared over pro-
longed follow up. Although the magnitude of responses in 
TW2 was weaker than in TW1, comparison of all responses 
at the earliest time point revealed a strikingly signifi  cant cor-
relation (R2 = 0.52, P = 0.0011; Fig. 4 A), which is in con-
trast to the CD8 T cell responses in acutely infected individuals 
reported to date (13). [ID]FIG4[/ID]
Figure 1.  The three siblings shared the same infecting virus and 
had similar clinical evolution. (A) Maximum likelihood tree reconstructed 
from HIV-1 pol sequences (corresponding to protease and fi  rst 235 amino 
acids of reverse transcriptase) in the three brothers’ viruses over the study 
period compared with other contemporary viral isolates of treatment-naive 
subjects in the same city (open circles) and the reference strain HXB2 
(closed circle), used as outgroup. The HKY85 with gamma distribution 
(HKY+I+G) model was used, which accounts for a transition/transversion 
bias, variable base frequency data, and variable substitution rates at differ-
ent nucleotide positions. Scale bar represents 1% genetic distance (0.01 
substitutions/site). Bootstrap values are shown at nodes with >70% sup-
port. (B) Plasma viremia and CD4 cell counts over time for all three siblings.JEM VOL. 203, March 20, 2006  531
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These initial T cell responses were followed using longi-
tudinally obtained cryopreserved PBMCs. By 34 mo after 
  infection, 14 of the 15 concordant initial responses were still 
detectable (Fig. 3 A). The only response that was completely 
lost was the same in both subjects, a B*4001-restricted re-
sponse in Gag. Longitudinal quantitation of the magnitude of 
responses by IFN-γ Elispot revealed that 11 of the 15 con-
cordant initial responses (including both of the early immuno-
dominant responses) remained similar in both twins: 7 
persisted in both, and 4 declined in both.
Over time, new responses became detectable to six epi-
topes in TW1 and fi  ve in TW2, four of these were targeted 
by both (Fig. 3 C), and all were subdominant responses. 
After 3 yr of persistent viremia, TW1 and TW2 both tar-
geted 22 epitopes; 20 of the epitopes were targeted by both 
twins. Although the distribution was less even, the correla-
tion remained statistically signifi  cant (R2 = 0.30, P = 0.007; 
Fig. 4 B).
Immune selection pressure within targeted 
CD8 T cell epitopes
We next evaluated the impact of persistent T cell responses 
on viral evolution by sequencing the targeted regions of the 
virus from both subjects. We initially concentrated on those 
responses that declined in both twins because the declining 
CD8 T cell responses have been associated with eff  ective im-
mune escape (14, 15). The response to the initially dominant 
B*4001-  restricted Pol epitope declined in both subjects, with 
similar kinetics (Fig. 5 A), and was associated in both subjects 
with a conversion from wild-type sequence present 6 mo af-
ter infection to the same Q→E mutation at position 6 in the 
epitope later in infection (Fig. 5 B), which was no longer 
recognized (Fig. 5 C). [ID]FIG5[/ID] TW1 developed an additional I→V 
mutation at position 1 of the epitope at 34 mo after infection, 
which was likewise not recognized  (unpublished data). In 
contrast, the immunodominant B*4001 Nef epitope that was 
persistently targeted remained unchanged in both subjects 
(unpublished data).
Similar results were found for the other epitopes that 
were initially targeted and subsequently declined in both 
Figure 2.  Similar distribution and magnitude of antigen-specifi  c 
T cell responses in both twins early after infection. IFN-γ T cell re-
sponses in TW1 and TW2 at the fi  rst available time point (6 mo) after 
infection expressed as SFCs per million PBMCs. The x axis represents all 
410 overlapping peptides spanning all HIV proteins. Each bar represents 
one response. Stars indicate responses not shared by the twins.
Figure 3.  T cell responses during the course of the study. Left pan-
els correspond to TW1 and right panels correspond to TW2. Open bars 
show the responses at 6 mo after infection and closed bars show the 
responses at 34 mo after infection. Responses targeted by both twins at 
the fi  rst study time point (A), responses targeted by only one of the twins 
at the fi  rst study time point (B), and new responses arising during 
the disease course in one or both of the twins (C). Details on epitope 
  sequences can be found in Tables S1–S3 (available at http://www.jem.
org/cgi/content/full/jem.20052116/DC1).
Figure 4.  Comparison of the magnitude of T cell responses be-
tween twins. Each square represents one T cell response. The x axis rep-
resents the magnitude of the response for TW1, and the y axis represents 
the magnitude of the response for TW2. (A) The responses at 6 mo after 
infection. (B) The same analysis at 34 mo after infection. Identical initial 
responses are as shown as closed squares and different responses or re-
sponses coming up later in the disease course are shown as open squares.532  CONSTRAINTS ON HIV-1 EVOLUTION AND IMMUNODOMINANCE | Draenert et al.
twins (Table I). [ID]TBL1[/ID] For three of four concordant declining re-
sponses, mutations arose at the identical amino acid positions. 
For the Gag IL10 response, viral evolution within the epitope 
was identical, with the same amino acid change (D; codon: 
GAC in both) occurring at a similar time point. The Env 
QL10 epitope was associated with a mixture at position 5 
of the wild-type amino acid N and the substitution K in both 
twins, which additionally developed substitution S at later 
time points. Both mutations (K and S) led to loss of recogni-
tion. The fourth concordant declining response was to the 
A2 restricted epitope YV9 in Pol. TW1 developed a V→I 
mutation at position 9 of the epitope that did not infl  uence 
peptide recognition. TW2 did not develop any mutations 
within the epitope. There were also no additional mutations 
in the immediate fl  anking region of this epitope detectable 
(unpublished data), thus the cause of decline of the response 
remains unclear.
Viral evolution within discordant CD8 T cell responses
We next examined the four subdominant CD8 T cell re-
sponses in which the response decreased in one twin and 
persisted in the other. Table II summarizes the sequence data 
for these responses. [ID]TBL2[/ID] In three cases, TW1 lost the response. In 
one case, the response was only lost in TW2. For all four epi-
topes, viral evolution was diff  erent, providing an explanation 
for the diff  erential eff  ect on established cellular responses.
The fi  rst example is the epitope IL8 in Pol (Fig. 5 D), 
which fi  ts the B*4001 motif but for which there were insuf-
fi  cient cells to formally demonstrate HLA restriction. The re-
sponse to this epitope decreased in TW1, whereas it persisted 
in TW2. TW1 developed an E→D mutation at position 2, 
which became dominant; in contrast, TW2 developed a mu-
tation at position 7 (K→R), but this remained a minor spe-
cies (Fig. 5 E). Both mutations led to a loss of recognition of 
this epitope in peptide titration assays (Fig. 5 F) and indicate 
that there was immune selection pressure being applied to 
this epitope in both twins, but only the virus in TW1 had 
successfully escaped recognition, as indicated by the declining 
CD8 T cell response.
TW1 developed the T→V mutation in A2 SL9 that was 
just recently described as an escape mutation (16), whereas 
the wild-type epitope persisted, as did the response, in TW2. 
For the initially strong Cw3 restricted epitope AL9 in Nef, 
TW1 showed changes at position 5, whereas TW2 devel-
oped a position 1 mutation. The latter mutation was associ-
ated with a drop in CD8 T cell responses in TW2 in vivo, 
but neither mutant aff  ected in vitro recognition, suggesting 
antigen processing changes, as recently described (17, 18). 
The fourth discordant response was to epitope LS9 in Nef, 
which was shown to be presented by both B*4001 and B*50 
(unpublished data). Both subjects developed a mutation at 
diff  erent positions of the epitope: the E→D in TW1 led to 
complete loss of recognition. The I→V peptide is still recog-
nized only two logs less well than the wild-type epitope, 
which may explain why the response persisted in TW2.
Thus, among the discordant CD8 T cell responses that 
evolved over time, all occurred within initially subdominant 
epitopes and there was heterogeneity in terms of the muta-
tions that arose. These data suggest that there are diff  erences 
in the kinetics of escape within the subdominant epitopes and 
are consistent with there being limited mutations leading to 
functional CD8 T cell escape (defi  ned by a declining CD8 
T cell response) within a given epitope.
Relationship between Shannon entropy scores 
and mutational escape
To further examine potential structural limitations aff  ecting 
escape mutations, we examined the relationship between 
emerging escape mutations and population sequence diver-
sity reported at each of these amino acid residues among re-
ported clade B isolates in the Los Alamos National Laboratory 
HIV Sequence Database (www.hiv.lanl.gov). Quantifi  cation 
of sequence diversity for each residue in the escaping muta-
tions was determined using normalized Shannon entropy 
scores (19). 9 of 12 escaping residues from the epitopes pre-
sented in Tables I and II arose at the most variable residue in 
each epitope (Table S4, available at http://www.jem.org/
cgi/content/full/jem.20052116/DC1). The remaining three 
Figure 5.  Concordant and discordant antigen-specifi  c T cell re-
sponses and viral evolution in both twins. Concordant (A–C) and dis-
cordant (D–F) CD8 T cell responses and viral evolution. (A) Magnitude of 
the CD8 T cell response toward the B*4001-restricted epitope Pol IL9 in 
TW1 and TW2 over the study period. (B) Sequence data of the autologous 
virus of TW1 and TW2 for this epitope at designated time points. Se-
quences are shown as bulk sequences. The Q→E substitution at position 6 
corresponds to the same nucleotide change, CAA→GAA. Lowercase un-
derlined letters indicate the dominant amino acid in population-based 
sequences showing mixtures of nucleotides. (C) Peptide titration assays 
using the wild-type peptide and the mutated peptide as antigen in Elispot 
assay. Frozen PBMCs were used as effectors. (D) Magnitude of the CD8 T 
cell response toward the epitope IETVPVKL in TW1 and TW2 over the study 
period. (E) Sequence data of the autologous virus of TW1 and TW2 for this 
epitope at designated time points. Sequences are shown as bulk se-
quences. Lowercase underlined letters indicate the dominant amino acid 
in population-based sequences showing mixtures of nucleotides. In addi-
tion, clonal data are shown for TW2 at 34 mo. (F) Peptide titration assays 
using the wild-type peptide and the mutated peptides as antigen in 
Elispot assay. Frozen PBMCs were used as effectors.JEM VOL. 203, March 20, 2006  533
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mutations still occurred at highly variable residues, but in 
the context of other more highly variable residues in each 
epitope. These results indicate that the escape mutations are 
preferentially occurring at residues that are more prone to 
  sequence variation, and support the conclusion that there are 
constraints to the allowable mutations that can occur within 
CD8 T cell epitopes.
Immodominance and HIV evolution of the twins’ virus 
in a partially HLA-matched environment
In this study, we also had the opportunity to evaluate the 
predictability of our fi  ndings in a third brother who shared 
half the HLA class I alleles with the twins and who became 
infected through needle sharing with them 13 mo after they 
became infected. He shared HLA-B*4001 with the twins, 
and again the B*4001 KL9 Nef epitope was the immuno-
dominant response in BR3 at the earliest time point. How-
ever, there was no detectable response to the B*4001-restricted 
epitope IL10 in Gag (Fig. 6 A).[ID]FIG6[/ID] Sequence data in BR3 within 
this epitope showed that all viral clones contained the E→D 
mutation at position 2 that arose in the twins before infection 
of BR3. We were unable to detect a reversion of this muta-
tion during 20 mo of follow up which was the last sample we 
could obtain in this subject (Fig. 6 B). In addition, we were 
unable to demonstrate a memory response to this epitope af-
ter in vitro stimulation with the B*4001-restricted peptide 
IL10 (Fig. 6 C). Together, these data suggest that BR3 was 
infected with an escape mutant in the B*4001 epitope IL10 
and never mounted a response to this region. Moreover, the 
longitudinal data suggest that this epitope mutation is stable 
and does not readily revert.
Evolution of neutralizing antibody responses
The similarity in adaptive immune responses and viral evolu-
tion demonstrated by examination of CD8 T cell responses 
prompted us to evaluate the evolution of virus-specifi  c 
humoral immune responses in each subject and compare the 
phenotypic ability of the viruses to escape autologous and 
heterologous neutralizing responses.
All viruses collected from the twins over the fi  rst 34 mo 
of infection were determined to use CCR5 for viral entry   
(unpublished data). Based on the neutralization of virus enve-
lope pools by autologous plasma samples, antibody titers were 
low (inhibitory concentration of <100-fold dilution) for 
contemporaneous plasma and were higher against viruses 
from preceding bleeds and increased over time. Detectable 
Table I. Autologous sequences of concordant decreasing CD8 T cell responses
Epitope 
(HXB2 aa position)
Time after 
infection
Sequence
TW1
Magnitude
TW1
Sequence
TW2
Magnitude
TW2
Impact on peptide 
recognition
mo
Pol
B4001 IL9 (357–365)
6
34
IEELRQHLL
V----E--- ↓
IEELRQHLL
-----E--- ↓
-----E--- ↓
V----E--- ↓
Gag
B4001 IL10 (92–101)
6
34
IdIKDTKEAL
-D-------- ↓
IdIKDTKEAL
-D-------- ↓
-D--------↓
Env
B4001 QL10 (805–814)
6
34
QELKnSAVSLa
----k-----b ↓
QELKnSAVSLa
↓
----S----- ↓
----K----- ↓
Pol
A2 YV9 (282–290)
6
34
YTAFTIPSV
--------I ↓
YTAFTIPSV
--------- ↓
--------I ↔
Lowercase underlined letters indicate the dominant amino acid in sequences showing mixtures of nucleotides.
<REF>a
</REF>Clonal analysis showed mixtures of amino acids N and K.
<REF>b
</REF>Clonal analysis showed mixtures of amino acids N, K, and S after 34 mo of infection.
Magnitude, magnitude of CD8 T cell response; ↓, decreasing; ↔, no difference.
Table II. Autologous sequences of discordant CD8 T cell responses (persistent vs. decreasing)
Epitope 
(HXB2 aa position)
Time after 
infection
Sequence
TW1
Magnitude
TW1
Sequence
TW2
Magnitude
TW2
Impact on peptide 
recognition
mo
Pol
B4001 IL8 (160–167)
6
34
 IETVPVKL
 -D------ ↓
 IETVPVKL
 ------r- ↔
-D------ ↓
------R- ↓
GagA2
SL9 (77–85)
6
34
 SLYNTVATL
 -------V- ↓
 SLYNTVATL
 --------- ↔
-------V- ↓
Nef
Cw3 AL9 (83–91)
6
34
 AALDMSHFL
 ----I---- ↔
 AALDLSHFL
 G-------- ↓
----M---- ↔
----I---- ↔
Nef
B50/B4001 LS9 (37–45)
6
34
 LEKHGAITS
 -D------- ↓
 LEKHGAITS
 ------V-- ↔
-D------- ↓
------V-- ↓
Lowercase underlined letters indicate the dominant amino acid sequences showing mixtures of nucleotides. Magnitude, magnitude of CD8 T cell response; ↓, decreasing;
↔, persistent/no difference.534  CONSTRAINTS ON HIV-1 EVOLUTION AND IMMUNODOMINANCE | Draenert et al.
levels of neutralizing antibody to the early autologous virus 
were found at 6 mo after infection for the three individuals. 
Neutralization antibody titers to the early autologous virus 
reached a peak (inhibitory concentration of >1,000-fold 
  dilution) 34 mo after infection (Fig. 7) and were highest with 
the fi  rst virus and decreased with each subsequent virus. [ID]FIG7[/ID] Both 
twins had a similar profi  le of neutralization to their own vi-
ruses at every time point tested. Notably, cross-neutralization 
assays revealed the twin’s plasma to have a similar profi  le of 
neutralization to each other’s viruses, in marked contrast to 
the low cross-neutralization between closely related viral 
strains in studies reported to date (20, 21). Moreover, BR3 
did not develop potent cross-neutralization antibodies to 
twins’ isolates or to control viruses.
It has been recently shown that neutralizing antibody re-
sponses play a pivotal role in the diversifi  cation of HIV-1 
envelope during early stages of infection (22). Therefore, we 
compared the patterns of clonal evolution of the env gene 
between the three siblings. We estimated average pairwise 
dN and dS between the viruses isolated at the fi  rst available 
sample and subsequent viral samples (Fig. 8). [ID]FIG8[/ID] The rate of 
nonsynonymous divergence averaged over the study period 
was higher than the synonymous divergence rate in the three 
patients (1.31 ± 0.24, 1.24 ± 0.16, and 1.54 ± 0.38 for 
TW1, TW2, and BR3, respectively). The amino acid sites 
subject to substantial selective pressure were clustered in the 
fi  ve variable regions of gp120 and at few positions in gp41, 
specifi   cally two positions in membrane-proximal regions, 
and four positions in the cytoplasmic tail (unpublished data). 
The patterns of glycosylation for the diff  erent variable re-
gions of the viral envelope were relatively stable during the 
fi  rst two years of infection and similar among the three 
  siblings (Fig. S1, available at http://www.jem.org/cgi/ 
content/full/jem.20052116/DC1). Finally, we looked for 
changes in the length of the variable regions in env. Although 
the twins showed similar patterns of deletions over time in 
V1 and V4 and insertions in V2 and V5, most of them hap-
pening earlier in TW2, BR3 showed little length variation 
over time (Fig. S2). These data indicate that both viral evolu-
tion and humoral immune response evolution are strikingly 
similar within the same host genetic background, suggesting 
that there are restrictions governing adaptive neutralizing 
immune responses and pathways to immune escape from 
these responses.
DISCUSSION
We present evidence that despite extensive HIV sequence 
variation within and among infected persons, there is pre-
dictability not only in the viral epitopes targeted but also in 
subsequent HIV evolution under immune selection pressure 
in the same genetic background after acute infection. These 
monozygotic twins infected simultaneously with the same 
  virus experienced a similar clinical course, as well as marked 
similarity in breadth and magnitude of CD8 T cell responses 
and neutralizing antibody responses. Moreover, viral evolu-
tion within regions targeted by both cellular and humoral im-
mune responses demonstrated a striking degree of similarity. 
Together these data infer substantial constraints on viral 
  evolution under adaptive humoral and cellular immune 
  selection pressure.
The similarity in early viral evolution under adaptive im-
mune selection pressure was observed for both T cell and 
antibody responses. For each twin, 15 of 16 initially detected 
immune responses were identical. The early immunodomi-
nant T cell responses were also identical, and for the four 
initial CD8 T cell responses that declined, indicating eff  ec-
tive immune escape, three occurred with mutation at the 
same residue and two because of the same amino acid substi-
tution. Early neutralizing antibody responses likewise re-
vealed similar patterns of evolution of the env gene and 
Figure 6.  Comparative antigen-specifi  c T cell responses and viral 
evolution between the twins and their brother. (A) Magnitude of the 
B*4001-restricted CD8 T cell responses over time. (left) Solid line, TW1; 
dotted line, TW2; (right) BR3. (B) Bulk and clonal sequence data of the 
autologous virus in all three brothers at designated time points for the 
Gag B4001 IL10 epitope. Lowercase underlined letters indicate the domi-
nant amino acid in population-based sequences showing mixtures of 
nucleotides. (C) Intracellular cytokine staining using in vitro–grown, pep-
tide-stimulated CD8 T cell lines and a synthetic peptide as antigen. For 
TW2, the CD8 line was grown from frozen PBMCs at month 34. For BR3, 
the CD8 line was grown from frozen PBMCs at month 29 (16 mo after 
infection). The magnitude of the ex vivo Gag B4001 IL10 response was 
0 SFCs/million PBMCs for both at the mentioned time point.JEM VOL. 203, March 20, 2006  535
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occurred similarly in both twins’ viruses (21, 23). The con-
tinuous ongoing accumulation of amino acid substitutions 
was probably the main component driving diversifi  cation of 
envelope to allow escape from neutralizing antibodies (22). 
However, changes in the length of variable loops that bind 
antibodies and glycosylation patterns may also play a second-
ary role. Thus, even for the highly variable env gene, the data 
suggest that there are substantial constraints on evolution un-
der immune selection pressure.
Although there have been other instances of HIV infec-
tion occurring in siblings, data have been lacking that have 
simultaneously examined immune responses and viral evolu-
tion in the context of initially identical host and viral genetics 
early in infection. HLA identical triplets infected by the same 
blood pack on the fi  rst day of their lives (24) were shown 
to exhibit remarkably uniform clinical manifestations with 
a very similar decline in CD4 counts and the same oppor-
tunistic infections occurring at approximately the same age; 
unfortunately, adaptive immune responses were not charac-
terized. The importance of examining events after acute in-
fection is suggested by the discordant responses observed 10 yr 
after infection in a study of selected CD8 T cell responses in 
hemophiliac brothers (2 yr apart in age) with the same class 
I A, B, and C alleles who were presumably infected by the 
same batch of HIV-contaminated factor VIII concentrate (8) 
and in identical twins infected by a blood pack within the 
fi  rst days of their lives whose CTL responses were studied 16 yr 
after infection using expanded CD8 lines (10). In both of 
those later stage studies, CD8 T cell responses diff  ered sub-
stantially. In contrast, the current study showed remarkable 
similarity at the earliest time point after acute infection, but 
more discordance over time. Using the most comprehensive 
methodological approach available to date, we demonstrate 
that the overall CTL response in acute infection is almost the 
same.  This is true not only for the immunodominant but 
also for the subdominant epitopes. We therefore conclude 
that CTL responses are determined by HLA and viral se-
quence despite the fact that the rearrangement of the TCR is 
a stochastically determined event. Moreover, the present data 
show concordance not only for the CD8 T cell response but 
also for the antibody response.
The current study also provides insights into immuno-
dominance in the setting of the same genetic background. 
Both twins showed the same pattern of immunodominance, 
and in neither twin did a late arising response ever become 
dominant. That there is something intrinsic to the particular 
epitope and HLA allele that confers immunodominance is 
suggested by the data from BR3 (who shares half the genetic 
background and half of the HLA alleles with the twins), in 
whom HLA-B*4001 KL9 was the immunodominant epitope 
and two additional B*4001 epitopes were the same as those 
Figure 7.  Antibody-neutralizing titers of TW1, TW2, and BR3 
plasma against autologous and heterologous viruses. The autologous 
neutralizing antibody responses are displayed for TW1 (A), TW2 (B), and 
BR3 (C). The heterologous neutralizing antibody responses are displayed 
for TW1 plasma samples against TW2 viruses (D), for TW2 plasma samples 
against TW1 viruses (E), and for BR3 plasma against TW2 viruses (F). 
  Antibody-neutralizing titers of BR3 plasma against TW1 viruses were 
similar to TW2 viruses. All time points refer to the twins infection; BR3 
was infected with the twins’ virus  13 mo later. (C) Open circles indicate 
samples that were available only for BR3.
Figure 8.  Accumulation of amino acid substitutions drives 
  diversifi  cation of envelope to allow escape from neutralizing 
  antibodies. Nonsynonymous (dN) and synonymous (dS) divergence 
from baseline virus (in percent) over time, averaged over the whole en-
velope sequence. Numbers in brackets refer to the estimated time of 
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recognized by the twins. Reasons for immunodominance of 
specifi  c epitopes remain to be defi  ned, but our data are in 
concordance with studies in SIV infection in macaques and 
acute HIV infection in humans (25–28). The existing HLA 
class I allele is an important predictor for the T cell response 
and immunodominance. Although immunodominance per 
se was not examined with respect to the neutralizing anti-
body responses, the fact that the twins were able to cross-
neutralize each other’s viruses and that sequence evolution 
was similar suggest that there may also be predictability to 
humoral immunodominance.
Partial immune selection pressure leading to predictable 
amino acid substitutions is perhaps not unanticipated given 
what has been reported in humans as a consequence of partial 
antiviral drug selection pressure with certain antiviral drugs. 
The predictability of immune escape is also suggested by stud-
ies showing allele-specifi  c polymorphisms in chronic infec-
tion (29, 30). The development of identical escape mutations 
in the same epitope has been described, e.g., the HLA-B57 
restricted epitope ISPRTLNAW (31, 32) and the HLA-A24 
restricted epitope KYKLKHIVW (17). On the other hand, 
there are clearly some epitopes that have multiple pathways to 
immune escape. Examples are the Tat epitope STPESANL in 
SIV infection, which escapes very early in infection (25), and 
the Gag epitopes K  R  W  I  I  M  G  L  M  K   (33, 34), SLYNVATL 
(16, 17), and T  S  T  L  Q  E  Q  I  A  W   in HIV infection (31, 35).
If any randomly selected mutation can confer a selective 
advantage to the virus, such as nonrecognition by a CTL re-
sponse, the corresponding quasispecies will overtake the 
others, following a Darwinian selection process. The rapidity 
of this process depends on the level of the selective advan-
tage conferred by the mutation, the prevalence of the mu-
tant within the virus population, and the operating pressure 
of the host immune response. This can therefore explain 
why an escape mutation arises earlier in one twin and later in 
the other.
This study also provides additional evidence for transmis-
sion of viruses containing CD8 T cell escape mutations, in 
this case into an HLA-similar recipient without reversion and 
the failure of the recipient to mount a CD8 T cell response 
toward this epitope, as previously reported for transmission of 
an escape mutation in an HLA-B27 restricted epitope from 
the mother to the child (36). Clearly there are diff  erences in 
stability of escape mutations: a specifi  cally engineered SIV 
strain containing escape mutations for three dominant epi-
topes was preserved when HLA-similar animals were infected 
(37), whereas mutation in a dominant A3 restricted HIV epi-
tope transmitted into an HLA-A3–positive recipient reverted 
back beginning 482 d after infection. In this case, the subject 
mounted a response toward the A3 epitope after the wild-
type sequence reappeared (38). We were unable to detect re-
version in BR3, but our follow-up period consisted of only 
20 mo. It is likely that escape mutations will need to be stud-
ied individually to defi  ne those with a propensity for rever-
sion and those that become stable, both of which have 
implications for HIV immunogen design.
In conclusion, monozygotic twins infected with the same 
virus showed considerable concordance of humoral and cellu-
lar immune responses and HIV evolution during the critical 
early phase of infection. The results, compared with a third 
brother who was acutely infected with the twins’ virus  13 mo 
later, indicate a striking degree of concordance in immune 
  selection pressure and viral evolution in HIV infection. The 
defi  nition of preferred pathways to immune escape under 
dominant immune selection pressure provides important infor-
mation for immunogen design that may allow one to immu-
nize not only against the prevalent strains, but also against what 
HIV will evolve to become under immune selection pressure.
MATERIALS AND METHODS
Study subjects. Subjects TW1 and TW2 are identical twins 21 yr old at the 
time of HIV infection through injection drug use. Both had a negative HIV-1 
ELISA in December 1998 and a seropositive result in September 1999.
Both shared needles with the same HIV+ person at the same time and no 
other persons. BR3 is a third brother, 3 yr older than the twins, who shared 
needles with them. His HIV-1 ELISA was negative in December 1999 and 
positive in November 2000. All three were hepatitis C virus coinfected. 
None was treated with antiretroviral therapy and none experienced an op-
portunistic infection during the study period. All three gave informed con-
sent for participation in this study. This study was approved by the Hospital 
Universitari Germans Trias i Pujol review board on biomedical research. 
Pertinent laboratory data are outlined in Fig. 1 B.
Zygosity assay and HLA tissue typing. Zygotic identity of the twins was 
assessed by analysis of polymorphic short tandem repeat loci by using the 
AmpFlSTR profi  ler PCR amplifi  cation kit (Applied Biosystems; reference 
<CIT>39</CIT>). Analysis of the PCR products was performed on the genetic analyzer. 
Fragment size determination was done with GeneScan v3.7 (Applied Biosys-
tems). Genotyper v3.7 was used for allele designation with respect to an al-
lelic ladder. HLA tissue typing was performed by high resolution sequencing 
for HLA-A and -B. HLA-C was typed by serology. The twins’ HLA class I 
genotype was as follows: A0201/2402; B4001/5001; Cw03/04. BR3’s HLA 
class I genotype (A0201/0201; B4001/44; Cw03/05) matched at a single al-
lele at each of the A, B, and C loci.
Isolation of PBMCs and generation of CD8 lines and BLCLs. Anti-
gen-specifi  c CD8 T cell lines were generated from cryopreserved PBMCs 
stimulated with 40 μg of synthetic peptide in the presence of 20 million 
  irradiated feeder PBMCs in R10 medium (RPMI 1640 [Sigma-Aldrich] 
supplemented with 2 mM l-glutamine, 50 U/ml penicillin, 50 μg/ml strep-
tomycin, 10 mM Hepes, and 10% heat-inactivated FCS [Sigma-Aldrich]). 
The following day, 50 U/ml of recombinant interleukin-2 was added. EBV-
transformed B lymphoblastoid cell lines (BLCLs) were established as de-
scribed previously (40).
Peptides. 410 peptides (15−19 amino acids long and 10–amino acid over-
lap; consensus sequence clade B 2001 [http://hiv-web.lanl.gov]) spanning all 
expressed HIV proteins were synthesized on an automated peptide synthe-
sizer (MBS 396; Advanced Chemtech) using fl  uorenylmethoxycarbonyl 
chemistry. Peptide truncations for epitope mapping and peptides corre-
sponding to the known optimal epitopes for the subjects’ HLA alleles were 
also synthesized. Peptides were used at 14 μg/ml for screening purposes and 
140 to 0.00014 μg/ml for titration assays.
Elispot assay. HIV-1–specifi  c CD8 T cell responses were quantifi  ed by 
IFN-γ Elispot assay using fresh or frozen PBMCs (0.5–1 × 105 per well), as 
described previously (41). The incubation period was 14 to 16 h. IFN-γ–
producing cells were counted by direct visualization and are expressed as 
spot-forming cells (SFCs) per 106 PBMCs. Negative controls were always JEM VOL. 203, March 20, 2006  537
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<30 SFCs per 106 input cells. The positive controls consisted of incubation 
of PBMCs with phytohemagglutinin. Wells were counted as positive if they 
were at least 50 SFCs/106 PBMCs and at least three times above background 
(12). We chose an upper cut-off   of 200 spots per well, i.e., 2,000 SFCs/106 
PBMCs when adding 105 PBMCs per well and 4,000 SFCs/106 PBMCs 
when adding 105 PBMCs per well. Responses to adjacent overlapping pep-
tides were counted as responses to one epitopic region because some T cell 
epitopes can be located in the overlapping region of two adjacent peptides, 
resulting in responses to both overlapping peptides (42).
Fine mapping of epitopes by Elispot assay was performed as described 
(43), using peptide truncations. In brief, 0.5–1 × 105 eff  ectors/well were in-
cubated with concentrations of peptides ranging from 140 to 0.00014 μg/ml 
overnight on the Elispot plate. All assays were run in duplicate. The optimal 
peptide was defi  ned as the peptide that induced 50% maximal specifi  c IFN-γ 
production of T cells at the lowest peptide concentration.
Intracellular cytokine staining for IFN-𝗄 production. For determina-
tion of HLA class I restriction of CD8 T cell responses, intracellular cytokine 
staining assays using autologous or HLA partly matched BLCLs were per-
formed as described elsewhere with minor modifi   cations (43). In brief, 
BLCLs were pulsed with 2 μg of peptide for 1 h and washed three times. 
They were then incubated with eff  ector cells (5 × 105 cells of CD8 line and 
5 × 104 BLCLs; E/T = 10:1) in FACS tubes and 1 μg/ml of the costimula-
tory mAbs anti-CD28 and anti-CD49d (BD Biosciences) at 37°C and 5% 
CO2 for 1 h before adding 10 μg/ml Brefeldin A (Sigma-Aldrich). After a 
6-h incubation, the cells were washed with PBS/1% FCS and stained with 
surface antibodies anti–CD8-PerCP and anti–CD4-APC (BD Biosciences) 
at 4°C for 30 min. After washing again, PBMCs were fi  xed using Fixation/
Permeabilization kit A (Caltag Laboratories) and placed at 4°C overnight. 
Cells were permeabilized using Fixation/Permeabilization kit B (Caltag 
  Laboratories) and anti–IFN-γ–FITC (BD Biosciences) was added. Cells were 
analyzed on a FACS Calibur Flow Cytometer (BD Biosciences). For nega-
tive controls, cells were incubated with BLCLs without peptide, but were 
treated otherwise identically. A positive response was defi  ned as threefold 
above background.
Neutralizing antibody responses. Neutralizing antibody titers were de-
termined using the ViroLogic Phenosense Entry Assay that measures inhibi-
tion of a recombinant virus in a single replication cycle assay (20). Coreceptor 
tropism was determined by measuring the ability of recombinant viruses to 
infect U87 CD4/CXCR4 or CD4/CCR5 cell lines and verifi  ed by inhibi-
tion of infection by specifi  c coreceptor antagonists.
Sequencing of viral RNA or proviral DNA. Viral RNA was extracted 
from the subjects’ plasma using the QIAamp RNA viral mini kit (QIAGEN) 
or viral DNA was extracted from PBMCs using the Puregene DNA isolation 
kit (Gentra) according to the manufacturer’s protocol. Viral RNA was tran-
scribed into cDNA using the SuperScript First-Strand Synthesis System for 
RT-PCR (Invitrogen) and the sequence-specifi  c primers as described (44). 
DNA was amplifi  ed using nested PCR and primers as described (44). PCR 
cycling conditions were as follows: 94°C for 2 min, 35–40 cycles of 30 s at 
94°C, 30 s at 56°C, 1.5 min at 72°C, and a fi  nal extension of 68°C for 
20 min. In the nested PCR reaction, the extension time was shortened to 
1 min. Regions of interest were cloned: PCR fragments were gel purifi  ed 
(QIAquick gel extraction kit; QIAGEN) and cloned using the TOPO TA 
cloning kit (Invitrogen). Plasmid DNA was isolated using QiaPrep Turbo 
Miniprep (QIAGEN). PCR products or plasmid DNA were sequenced 
  bidirectionally by the Sequencing Core Facility at Massachusetts General 
Hospital (Boston, MA). Sequencher 4.1 (Gene Codes Corporation) was 
used to edit and align sequences.
Sequence analysis. HIV-1 RNA was extracted from plasma at diff  erent 
time points during follow up. Each subject’s virus isolates were processed in 
totally independent batches to avoid cross-contamination. Pol   (protease and 
the fi  rst 235 codons of the reverse transcriptase) and env (C2 to V5 regions) 
(45) fragments were reverse transcribed, PCR-amplifi  ed, and bidirectionally 
sequenced on a 3100 automatic sequencer (Applied Biosystems). In   addition, 
a total of 61 molecular clones encompassing the env gene were characterized 
for the three siblings at diff  erent time points.   Sequence alignments were ob-
tained using ClustalW (46) and manually edited in the regions of variable 
length in particular to suppress the gaps within N-  glycosylation sites (identi-
fi  ed using an NXYX motif where X is any amino acid except proline and 
Y is either serine or threonine). Maximum likelihood phylogenetic trees of 
each subject’s pol and env sequences were constructed using PAUP* version 
4.0b10 (47) under Modeltest 3.0 (48). The reliability of clustering in phylo-
grams was assessed by bootstrapping analyses (49).   Genetic distances and evo-
lutionary rates were computed using a Kimura 2 parameter model in MEGA 
(50). The nonsynonymous and synonymous substitution rates were calcu-
lated using the modifi  ed method of Nei and Gojobori (51) that considers 
a transition/transversion ratio of 2, as implemented in MEGA (50).
Statistical analysis. Correlation analysis was done using linear regression 
analysis with Graph Pad Prism, Version 4.0.
Online supplemental material. The online supplemental material shows 
the T cell responses at the fi  rst and last study time points (Tables S1−S3), the 
residue conservation within escaping CD8 epitopes in the twins’ viruses us-
ing clade B sequences (Table S4), the number of N-glycosylation sites over 
time for the variable loops of gp120, measured by using multiple clonal se-
quences (Fig. S1), and the length of the variable regions of the viral envelope 
(in amino acids) over time, measured by using multiple clonal sequences 
(Fig. S2). Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20052116/DC1.
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